Search results
Atosiban, sold under the brand name Tractocile among others, is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985.
Atosiban reduces the frequency of uterine contractions to delay pre-term birth in adult females and induces uterine quiescence 5, 1. Mechanism of action. Atosiban is a synthetic peptide oxytocin antagonist 5, 1. It resembles oxytocin with has modifications at the 1, 2, 4, and 8 positions.
Description: Mechanism of Action: Atosiban is an oxytocin peptide analogue.It competitively inhibits oxytocin receptors thereby causing a reduction in oxytocin-mediated release of inositol triphosphate (IP3) from myometrial cell membranes, which consequently causes decreased Ca release and extracellular Ca influx, ultimately causing a reduced frequency of uterine contractions.
Atosiban is a mixed oxytocin/vasopressin V1a receptor antagonist that provides an effective and more safety therapy than other tocolytic drugs to delay delivery, being more effective as gestation progresses and the expression of oxytocin receptor increases (Haas et al., 2012 ). The possible long-term consequences of the treatment with Atosiban ...
The active substance in Tractocile, atosiban, is an antagonist of the natural hormone oxytocin. This means that atosiban blocks the action of oxytocin. Oxytocin is the hormone involved in starting contractions of the womb. By blocking the action of oxytocin, Tractocile prevents contractions and causes the womb to relax, helping to delay birth.
